Process for the preparation of a solid pharmaceutical dosage...

Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Matrices

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C424S489000, C514S655000

Reexamination Certificate

active

06423342

ABSTRACT:

TECHNICAL FIELD
This invention relates to a process for the preparation of a solid pharmaceutical dosage form and solid pharmaceutical dosage forms produced by this process.
PREFERRED EMBODIMENT
Many solid pharmaceutical dosage forms, especially fast-dispersing dosage forms, are manufactured by processes which involve the steps of solidifying, for instance by freezing, a mixture of the active ingredient and a carrier in a solvent and subsequently removing the solvent from the solidified mixture by sublimation or some other means. However, some active ingredients are susceptible to the means used for removing the solvent, such as sublimation, or evaporation, during such manufacturing processes resulting in a loss of potency in the final product. Moreover, active ingredients which have been utilized in such manufacturing processes tend to adopt an amorphous structure which is chemically less stable than the crystalline form and this can contribute to a further loss of potency during manufacture and storage of the dosage form. Accordingly it is desirable to find a method of stabilizing such susceptible active ingredients during such manufacturing processes.
It is well known that many pharmaceutically active compounds are weak acids or weak bases. Accordingly, in solution, an equilibrium is established between the free acid and the salt form or the free base and the salt form. Moreover, there is often a considerable difference in volatility between the free acid or free base and the salt form. It has therefore been found that, by adjusting the pH of the solution containing the active ingredient, the equilibrium can be shifted to favor the less volatile form of the active ingredient whether it be the free acid or base or the salt form.
According to a first aspect of the present invention there is therefore provided a process for the preparation of a solid pharmaceutical dosage form comprising a carrier and, as active ingredient, a compound which is susceptible to either sublimation or evaporation during the preparation process, which process includes the steps of solidifying a mixture of the compound and carrier in a solvent and subsequently removing the solvent from the solidified mixture, characterized in that a pH modifier is added to the mixture prior to solidification.
Preferably, the solid pharmaceutical dosage form is a solid, fast-dispersing dosage form. Such fast-dispersing dosage forms typically disintegrate within 1 to 10 seconds of being placed in the oral cavity and many different examples of such dosage forms are already known.
For instance, U.S. Pat. No. 5,120,549 discloses a fast-dispersing matrix system which is prepared by first solidifying a matrix-forming system dispersed in a first solvent and subsequently contacting the solidified matrix with a second solvent that is substantially miscible with the first solvent at a temperature lower than the solidification point of the first solvent, the matrix-forming elements and active ingredient being substantially insoluble in the second solvent, whereby the first solvent is substantially removed resulting in a fast-dispersing matrix.
U.S. Pat. No. 5,079,018 discloses a fast-dispersing dosage form which comprises a porous skeletal structure of a water soluble, hydratable gel or foam forming material that has been hydrated with water, rigidified in the hydrated state with a rigidifying agent and dehydrated with a liquid organic solvent at a temperature of about 0° C. or below to leave spaces in place of hydration liquid.
Published International Application No. W093/12769 (PCT/JP93/01631) describes fast-dispersing dosage forms of very low density formed by gelling, with agar, aqueous systems containing the matrix-forming elements and active ingredient, and then removing water by forced air or vacuum drying.
U.S. Pat. No. 5,298,261 discloses fast-dispersing dosage forms which comprise a partially collapsed matrix network that has been vacuum-dried above the collapse temperature of the matrix. However, the matrix is preferably at least partially dried below the equilibrium freezing point of the matrix.
The term “fast-dispersing dosage form” therefore encompasses all the types of dosage form described in the preceding paragraphs. However, it is particularly preferred that the fast-dispersing dosage form is of the type described in U.K. Patent No. 1548022, that is, a solid fast-dispersing dosage form comprising a network of the active ingredient and a water-soluble or water-dispersible carrier which is inert towards the active ingredient, the network having been obtained by subliming solvent from a composition in the solid state, that composition comprising the active ingredient and a solution of the carrier in a solvent.
One example of an active ingredient which is susceptible to evaporation during such manufacturing processes is selegiline ((−)-N,&agr;-dimethyl-N-2-propynylphenethylamine) which is useful in the treatment of Parkinson's disease and it is therefore particularly preferred that the active compound is selegiline or an acid-addition salt thereof, especially the hydrochloride. Another suitable active ingredient is nicotine.
Clinical studies have shown that 23-52% of patients with Parkinson's disease have swallowing difficulties and many such patients tend to dribble. Accordingly, it is particularly desirable to be able to administer selegiline in a fast-dispersing dosage form which will disintegrate rapidly in the mouth thereby minimizing the above problems. Fast-dispersing dosage forms of selegiline may be prepared by first freezing unit doses of an aqueous dispersion of the drug and then removing the water by sublimation or some other suitable means. When in the solution phase, the selegiline will be in an equilibrium between the salt form and the free base. However, the free base of selegiline is a volatile oil which can evaporate during the manufacturing process or from the finished product. Accordingly, it is desirable in this case to shift the equilibrium towards the salt form by lowering the pH of the solution using a suitable pH modifier.
Suitable pH modifiers for lowering the pH of a mixture are generally acids, especially organic acids. Preferred acids include citric acid, tartaric acid, phosphoric acid, hydrochloric acid and maleic acid. Of these, citric acid is particularly preferred.
Clearly, there will be some cases where it will be desirable to increase the pH of the solution to favor the less volatile component. Suitable pH modifiers in this case are generally bases. Suitable inorganic bases include sodium hydroxide, potassium hydroxide and carbonates and bicarbonates of sodium and potassium and other suitable elements. Suitable organic bases include propanolamine, ethanolamine, methylamine, dimethyl formamide, dimethylacetamide, diethanolamine, diisopropanolamine and triethanolamine.
Typically, the pH modifier will comprise 0.25 to 0.75% by weight, especially 0.4 to 0.6% by weight, of the initial mixture, that is, before removal of the solvent. If less than 0.25% by weight is present, the equilibrium may not be significantly affected. However, if more than 0.75% by weight is used, this can have a deleterious effect on the physical properties of the dosage form.
It is also known that the amorphous state of a compound is a high energy state. Accordingly, holding such a compound in the solidified state at a particular temperature may encourage the compound to transform to the chemically more stable, lower energy, crystalline state. It is therefore also preferred that the process of the invention comprises the further step of maintaining the solidified mixture within a specific temperature range for a specified period of time prior to removal of the solvent. The compound then retains the crystalline structure so produced throughout the remainder of the manufacturing process with the result that the finished product is chemically more stable than product which has not been treated in this way.
It is also envisaged that this further step could be advantageously performed in the absence

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Process for the preparation of a solid pharmaceutical dosage... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Process for the preparation of a solid pharmaceutical dosage..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for the preparation of a solid pharmaceutical dosage... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2916713

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.